Explore the vast range of titles available.

A study was conducted to assess the safety and tolerability of the tetravalent live-attenuated dengue vaccine Qdenga®, which received marketing approval in Germany in 2022. The study evaluated vaccine-related reactions in a predominantly dengue-naïve population, highlighting the importance of post-marketing surveillance as an essential component of safety evaluation for newly licensed vaccines. Following dengue vaccination, participants were recruited for an anonymous online questionnaire through the national 'Trav VacNet' network in Germany. The questionnaire focused on post-vaccination reactions up to 18 days after the first and second vaccination, as well as previous travel history and coadministration. The study included 1176 participants, with a median age of 39 years (IQR 28-56), 53.2% female (n = 625), 46.5% male (n = 547), and 0.3% non-binary participants (n = 4). After the first dose, 51% of the participants reported systemic reactions such as headache [40% (190/474)], weakness [40% (189/474)], and malaise [32% (154/474)], which were most pronounced between days 7 and 11 post vaccination. After the second dose, localized signs and symptoms such as pain at the injection site [22% (n = 55/250)] were more common. Fever was more common after the first dose [20% (96/474)] vs. 2% (6/250) after the second. Females reported significantly more reactions than males after both vaccinations (1st dose P = 0.0002; 2nd dose P = 0.0003). A total of 334 (28%) co-administrations were reported whereby assessing adverse events were reported in 47% (157/333) of participants, with the highest prevalence observed when combined with the Japanese encephalitis vaccine [56.8%, (42/74)]. Differences in age groups were observed, with a decrease in reactions in the elderly (≥65 years). Vaccine-related reactions were frequently reported, predominantly after the first dose in dengue-naïve participants. Coadministration was a common strategy without significantly increasing side effects. The study provides important insights into reactogenicity and may help improve vaccination strategies in dengue-naïve populations.

This paper discusses challenges in formulating and harmonizing malaria prevention recommendations for travellers. It explores diverse approaches used by advisory groups to assess malaria risk and shares insights from the 2023 International Expert Committee for Travel Medicine meeting. It also explores future prospects for enhancing malaria prevention recommendations for travellers.

The expert committees for travel medicine of Belgium, Germany, The Netherlands and Switzerland endorse joint malaria prevention recommendations for travellers. Here, the methodological approach underlying these recommendations, including evidence sources used, risk category definitions and the role of expert opinion, is outlined.

Because of the worldwide engagement of the German armed forces, tropical diseases may come to the attention of their medical services. In particular, acquired malarial infections, which sometimes become symptomatic only months or even years after soldiers return from military operations, need to be addressed. Other forces, such as the British, U.S., Australian, and Italian armed forces, reported cases of vivax malaria up to approximately 20 months after soldiers returned from military operations. The importance of a sound history and rapid diagnosis, leading to appropriate treatment, is emphasized in this case report of a 27-year-old German soldier who reported for sick call in his unit complaining of a flu-like illness, which later proved to be vivax malaria. The special parasitological features of Plasmodium vivax infection are discussed.

The successful establishment and roll-out of a post-licensing surveillance network to assess the reactogenicity of rarely used new vaccines by anonymous data donation to rapidly share early experiences from daily practice.